John Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8754249/publications.pdf

Version: 2024-02-01

331259 197535 2,534 50 21 49 citations h-index g-index papers 52 52 52 3698 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 2010, 95, 284-292.	1.7	321
2	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncology, The, 2016, 17, 164-173.	5.1	283
3	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	0.6	268
4	Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infectious Diseases, The, 2013, 13, 519-528.	4.6	198
5	A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 2301-2309.	6.7	153
6	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	2.5	151
7	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e357-e366.	2.2	133
8	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	1.3	128
9	Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destruction. Arthritis and Rheumatism, 2007, 56, 753-764.	6.7	93
10	Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2007, 13, 601-607.	2.0	86
11	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research, 2005, 7, R80.	2.0	75
12	Endothelial Progenitor Cells, Angioblasts, and Angiogenesis—Old Terms Reconsidered From a Current Perspective. Trends in Cardiovascular Medicine, 2008, 18, 45-51.	2.3	63
13	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology, the, 2020, 7, e100-e111.	2.2	59
14	A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia. British Journal of Haematology, 2016, 172, 592-601.	1.2	39
15	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). Bone Marrow Transplantation, 2020, 55, 681-694.	1.3	39
16	IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine, 2010, 50, 58-68.	1.4	38
17	Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: The G-CSF in Angina with IHD to stimulate Neovascularization (GAIN I) trial. American Heart	1.2	31
18	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 2019, 54, 933-942.	1.3	25

#	Article	IF	CITATIONS
19	Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?. Supportive Care in Cancer, 2017, 25, 421-427.	1.0	23
20	A SYBR green-based real-time PCR method for detection of haemopoietic chimerism in allogeneic haemopoietic stem cell transplant recipients. European Journal of Haematology, 2006, 77, 425-431.	1.1	22
21	Detection of drug effects on gastric emptying and contractility using a wireless motility capsule. BMC Gastroenterology, 2014, 14, 2.	0.8	22
22	What They Want: Inclusion of Blood and Marrow Transplanation Survivor Preference in the Development of Models of Care for Long-Term Health in Sydney, Australia. Biology of Blood and Marrow Transplantation, 2016, 22, 731-743.	2.0	22
23	Profound thrombocytopenia related to G-CSF. American Journal of Hematology, 2007, 82, 229-230.	2.0	21
24	Stem cells in the aetiopathogenesis and therapy of rheumatic disease. Best Practice and Research in Clinical Rheumatology, 2001, 15, 711-726.	1.4	19
25	Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. Heart, 2012, 98, 282-290.	1.2	16
26	Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (<scp>BMT</scp>). Cancer Medicine, 2016, 5, 1702-1716.	1.3	15
27	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	0.8	14
28	A survey of infectious diseases and vaccination uptake in longâ€term hematopoietic stem cell transplant survivors in Australia. Transplant Infectious Disease, 2019, 21, e13043.	0.7	14
29	Small-Molecule Inhibitor of Glycogen Synthase Kinase 3β 6-Bromoindirubin-3-oxime Inhibits Hematopoietic Regeneration in Stem Cell Recipient Mice. Stem Cells and Development, 2015, 24, 724-736.	1.1	13
30	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Internal Medicine Journal, 2018, 48, 276-285.	0.5	13
31	Autologous Hematopoietic Stem Cell Transplant for Systemic Sclerosis Improves Anemia from Gastric Antral Vascular Ectasia. Journal of Rheumatology, 2015, 42, 554-555.	1.0	12
32	Nutritional issues and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia. Supportive Care in Cancer, 2017, 25, 137-144.	1.0	12
33	Fear of cancer recurrence following allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancy: A cross-sectional study. European Journal of Oncology Nursing, 2020, 49, 101845.	0.9	12
34	Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 798300.	2.2	12
35	Rituximab and its potential for the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 2006, 2, 207-212.	0.9	11
36	A phase <scp>II</scp> study of riskâ€adapted intravenous melphalan in patients with <scp>AL</scp> amyloidosis. British Journal of Haematology, 2012, 157, 766-769.	1.2	9

#	Article	IF	CITATIONS
37	Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. Cancer Medicine, 2016, 5, 3606-3614.	1.3	9
38	Early and Late Posttransplant Lymphoproliferative Disorder After Lung Transplantation—34 Cases From the European PTLD Network. Transplantation, 2013, 96, e18-e19.	0.5	8
39	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. Biology of Blood and Marrow Transplantation, 2020, 26, 1868-1875.	2.0	8
40	Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation. Reviews on Recent Clinical Trials, 2008, 3, 130-138.	0.4	8
41	Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. Bone Marrow Transplantation, 2018, 53, 1478-1482.	1.3	7
42	Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. Journal of Psychosocial Oncology, 2021, 39, 534-552.	0.6	7
43	Changes to work status and household income of long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia. Bone Marrow Transplantation, 2018, 53, 926-931.	1.3	6
44	Cushing's syndrome can precipitate diabetes but mask nonâ€Hodgkin's lymphoma. Medical Journal of Australia, 2008, 188, 262-262.	0.8	3
45	Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: a cross-sectional survey. Journal of Cancer Survivorship, 2022, 16, 432-444.	1.5	3
46	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplantation, 2022, 57, 982-989.	1.3	3
47	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	1,2	3
48	Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia. Bone Marrow Transplantation, 2021, 56, 514-516.	1.3	2
49	Stem cell transplantation in rheumatic diseases. APLAR Journal of Rheumatology, 2003, 6, 79-82.	0.2	0
50	Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index. Blood, 2021, 138, 3958-3958.	0.6	0